Page 200 - Drug Class Review
P. 200

(ITT-LOCF: -0.8 vs. -2.5 points; P = 0.02) in RIV (6-12 mg) than in placebo-treated patients. The difference
                                                                               Subgroup analysis of the pooled population presented that nicotine use attenuates the dose-response curve of
             Drug Effectiveness Review Project
                                                        Activity of daily living (PDS): Only RIV 6-12 mg showed a significant difference to placebo: PDS, placebo
                                                                                                                                                      Page 130 of 205
                                                                 Subgroup analysis stratifying by disease severity (GDS) found larger treatment differences (PDS) between
                                              RIV-treated patients experienced statistically significant better results than placebo-treated patients in:
                                RIV 1-4 mg/d or 6-12 mg/d (published trials) or 3 mg/d, 6 mg/d, 12 mg/d (unpublished) for 26 weeks
                                                 Cognition: ADAS-Cog,  placebo -2.65; 1-4mg – 1.81; 6-12mg 0.58; P < 0.005 (observed cases)









                                                    Global function: CIBIC-plus, placebo 4.35; 1-4mg 4.17; 6-12mg 4.01; P < 0.005






















                                                           -3.47; 1-4mg – 3.86; 6-12mg -0.78; P < 0.005




















                          Authors: Schneider et al; Potkin et al.; Burns et al.
                                                                        significance.    RIV and placebo in patients with more severe disease, but these differences did not reach statistical   RIV and older patients experienced greater benefit from RIV  Retrospective subgroup analysis of patients with moderately severe AD (n = 117; MMSE 10 – 12) revealed  a significantly smaller decline of ADAS-cog (ITT-LOCF: 0 vs. -6.1 points; P < 0.001) and MMSE scores  in ADL did not reach statistical significance (ITT-LOCF: -2.0 vs. -6.3; P = 0.065)  Not reported; Only the 3 included studies had been conducted at time of meta-analysis.








                                                                                                         NR                  NR        Fair











             Final Report Update 1     Years: 1998; 2002; 2004    CHARACTERISTICS OF   INTERVENTIONS:      MAIN RESULTS:      ADVERSE EVENTS:      COMPREHENSIVE  LITERATURE SEARCH   STRATEGY:     STANDARD METHOD OF  APPRAISAL OF STUDIES:      QUALITY RATING:         Alzheimer's Drugs
   195   196   197   198   199   200   201   202   203   204   205